GlassScriptPhysician profile
Keith R Slayden
NPI 1295257707
$8,963.86
in general payments reported to CMS, 2019-2025
31 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $442 · 2021: $792 · 2022: $1,509 · 2023: $1,521 · 2024: $2,082 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,498.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,137.40 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $956.29 | 2019-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Abbvie INC. | $861.85 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $719.39 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Novartis Pharmaceuticals Corporation | $648.65 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $587.44 | 2024-2025 | Xdemvy |
| Allergan, INC. | $571.62 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $413.02 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $318.15 | 2019-2021 | |
| Biotissue Holdings INC. | $282.35 | 2022-2024 | |
| Harrow Eye, LLC | $261.86 | 2024-2025 | Vevye, Iheezo, Triesence |
| Johnson & Johnson Surgical Vision, INC. | $252.40 | 2024 | Tecnis Iol |
| Apellis Pharmaceuticals, INC. | $212.49 | 2023-2024 | Syfovre |
| Horizon Therapeutics Plc | $212.45 | 2020-2023 | Tepezza |
| Genentech USA, INC. | $195.95 | 2024-2025 | Vabysmo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $181.26 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $177.12 | 2022-2025 | Tyrvaya |
| Glaukos Corporation | $147.09 | 2025 | Idosetr |
| Regeneron Healthcare Solutions, INC. | $137.53 | 2023-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $131.66 | 2022 | |
| Kala Pharmaceuticals, INC. | $127.41 | 2021 | |
| Amgen INC. | $99.28 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $62.81 | 2022-2025 | Yutiq, Purified Cortrophin Gel |
| Alimera Sciences, INC. | $54.04 | 2022-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $47.89 | 2023-2024 | Izervay |
| Sight Sciences, INC. | $43.89 | 2023-2024 | Tearcare System, Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $37.32 | 2019-2022 | |
| Rxsight INC | $34.13 | 2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Rayner Intraocular Lenses Limited | $22.06 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Ivantis, INC | $15.99 | 2020 | |
| Spark Therapeutics, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Slayden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.